Rockefeller Capital Management
TXG icon

Rockefeller Capital Management’s 10x Genomics TXG Stock Holding History

Rockefeller Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Sell
10,771
-11,060
-51% -$290K ﹤0.01% 2188
2026
Q1 		$463K Buy
21,831
+4,645
+27% +$92.9K ﹤0.01% 2015
2025
Q4 		$280K Buy
17,186
+10,830
+170% +$164K ﹤0.01% 2190
2025
Q3 		$74.3K Buy
+6,356
New +$82.9K ﹤0.01% 2729
2025
Q1 		– Sell
-16,705
Closed -$240K – 1737
2024
Q4 		$240K Sell
16,705
-799
-5% -$12.6K ﹤0.01% 1627
2024
Q3 		$395K Buy
17,504
+4,746
+37% +$98.1K ﹤0.01% 1500
2024
Q2 		$248K Sell
12,758
-1,288
-9% -$33.7K ﹤0.01% 1593
2024
Q1 		$527K Sell
14,046
-4,374
-24% -$192K ﹤0.01% 1456
2023
Q4 		$1.03M Buy
18,420
+7,762
+73% +$338K ﹤0.01% 1130
2023
Q3 		$440K Sell
10,658
-1,006
-9% -$52.3K ﹤0.01% 1321
2023
Q2 		$651K Buy
11,664
+1,165
+11% +$63.1K ﹤0.01% 1243
2023
Q1 		$584K Sell
10,499
-1,562
-13% -$72.9K ﹤0.01% 1286
2022
Q4 		$439K Buy
12,061
+9,186
+320% +$300K ﹤0.01% 1330
2022
Q3 		$81K Buy
2,875
+1,402
+95% +$53.4K ﹤0.01% 2110
2022
Q2 		$66K Sell
1,473
-3,835
-72% -$199K ﹤0.01% 2165
2022
Q1 		$402K Buy
5,308
+59
+1% +$5.16K ﹤0.01% 1403
2021
Q4 		$781K Buy
5,249
+921
+21% +$141K ﹤0.01% 1140
2021
Q3 		$629K Sell
4,328
-14,837
-77% -$2.55M ﹤0.01% 1176
2021
Q2 		$3.75M Buy
19,165
+9,534
+99% +$1.73M 0.02% 530
2021
Q1 		$1.74M Sell
9,631
-3,228
-25% -$557K 0.01% 621
2020
Q4 		$1.82M Buy
12,859
+2,639
+26% +$383K 0.01% 545
2020
Q3 		$1.27M Buy
10,220
+8,312
+436% +$873K 0.01% 536
2020
Q2 		$170K Sell
1,908
-309
-14% -$24.1K ﹤0.01% 1000
2020
Q1 		$138K Buy
+2,217
New +$173K ﹤0.01% 921

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rockefeller Capital Management's TXG Position: Q2 2026 in Review

Rockefeller Capital Management reduced its 10x Genomics (TXG) stake by 51% in Q2 2026, selling an estimated $290K and leaving 10,771 shares worth $413K. The position accounts for ﹤0.01% of the portfolio, ranked #2188.

Rockefeller Capital Management first reported a position in TXG in Q1 2020 and has held it in 24 quarters since. The position peaked at $3.75M in Q2 2021. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Rockefeller Capital Management held 10,771 shares of 10x Genomics worth $413K as of Q2 2026.
  • Rockefeller Capital Management sold 11,060 10x Genomics shares in Q2 2026, an estimated $290K.
  • 10x Genomics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2188 holding.
  • Rockefeller Capital Management first reported a position in 10x Genomics in Q1 2020 and has held it in 24 quarters since.
  • Rockefeller Capital Management's 10x Genomics position peaked at $3.75M in Q2 2021.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.